Novel insights into the link between fetal cell microchimerism and maternal cancers

Valentina Cirello, Laura Fugazzola

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Fetal cell microchimerism (FCM) is defined as the persistence of fetal cells in the mother for decades after pregnancy without any apparent rejection. Fetal microchimeric cells (fmcs) engraft the maternal bone marrow and are able to migrate through the circulation and to reach tissues. In malignancies, the possible role of fmcs is still controversial, several studies advising a protective and repairing function, and other postulating a beneficial role in the progression of the disease. At the peripheral blood level, FCM is less frequently observed in women with several solid and hematological neoplasia with respect to healthy controls, suggesting a beneficial role in cancer surveillance. At the tissue level, fmcs were documented in neoplastic lesions of thyroid, breast, cervix, lung and melanoma, displaying epithelial, hematopoietic, mesenchymal and endothelial lineage differentiation. Fmcs expressing hematopoietic markers were hypothesized to have a role in the attack to neoplastic cells, whereas those expressing epithelial or mesenchymal antigens could be involved in repair and replacement of damaged cells. On the other hand, fetal cells showing an endothelial phenotype could have a role in tumor evolution and progression. The positive effect of FCM is supported by findings in animal models. Conclusions: This review provides an extensive overview of the link between fetal cell microchimerism and maternal cancers. Moreover, biological mechanisms by which fetal cell microchimerism is believed to modulate the protection against cancer development or tumor progression will be discussed, together with findings in animal models.

Original languageEnglish
Pages (from-to)1697-1704
Number of pages8
JournalJournal of Cancer Research and Clinical Oncology
Volume142
Issue number8
DOIs
Publication statusPublished - 2016

Fingerprint

Chimerism
Mothers
Neoplasms
Animal Models
Cervix Uteri
Disease Progression
Melanoma
Thyroid Gland
Breast
Stem Cells
Endothelial Cells
Bone Marrow
Phenotype
Antigens
Pregnancy
Lung

Keywords

  • Cancer
  • Fetal cells
  • Microchimerism
  • Women

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Novel insights into the link between fetal cell microchimerism and maternal cancers. / Cirello, Valentina; Fugazzola, Laura.

In: Journal of Cancer Research and Clinical Oncology, Vol. 142, No. 8, 2016, p. 1697-1704.

Research output: Contribution to journalArticle

@article{4b51ef2128ea430491c0307fda033b8b,
title = "Novel insights into the link between fetal cell microchimerism and maternal cancers",
abstract = "Introduction: Fetal cell microchimerism (FCM) is defined as the persistence of fetal cells in the mother for decades after pregnancy without any apparent rejection. Fetal microchimeric cells (fmcs) engraft the maternal bone marrow and are able to migrate through the circulation and to reach tissues. In malignancies, the possible role of fmcs is still controversial, several studies advising a protective and repairing function, and other postulating a beneficial role in the progression of the disease. At the peripheral blood level, FCM is less frequently observed in women with several solid and hematological neoplasia with respect to healthy controls, suggesting a beneficial role in cancer surveillance. At the tissue level, fmcs were documented in neoplastic lesions of thyroid, breast, cervix, lung and melanoma, displaying epithelial, hematopoietic, mesenchymal and endothelial lineage differentiation. Fmcs expressing hematopoietic markers were hypothesized to have a role in the attack to neoplastic cells, whereas those expressing epithelial or mesenchymal antigens could be involved in repair and replacement of damaged cells. On the other hand, fetal cells showing an endothelial phenotype could have a role in tumor evolution and progression. The positive effect of FCM is supported by findings in animal models. Conclusions: This review provides an extensive overview of the link between fetal cell microchimerism and maternal cancers. Moreover, biological mechanisms by which fetal cell microchimerism is believed to modulate the protection against cancer development or tumor progression will be discussed, together with findings in animal models.",
keywords = "Cancer, Fetal cells, Microchimerism, Women",
author = "Valentina Cirello and Laura Fugazzola",
year = "2016",
doi = "10.1007/s00432-015-2110-3",
language = "English",
volume = "142",
pages = "1697--1704",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Novel insights into the link between fetal cell microchimerism and maternal cancers

AU - Cirello, Valentina

AU - Fugazzola, Laura

PY - 2016

Y1 - 2016

N2 - Introduction: Fetal cell microchimerism (FCM) is defined as the persistence of fetal cells in the mother for decades after pregnancy without any apparent rejection. Fetal microchimeric cells (fmcs) engraft the maternal bone marrow and are able to migrate through the circulation and to reach tissues. In malignancies, the possible role of fmcs is still controversial, several studies advising a protective and repairing function, and other postulating a beneficial role in the progression of the disease. At the peripheral blood level, FCM is less frequently observed in women with several solid and hematological neoplasia with respect to healthy controls, suggesting a beneficial role in cancer surveillance. At the tissue level, fmcs were documented in neoplastic lesions of thyroid, breast, cervix, lung and melanoma, displaying epithelial, hematopoietic, mesenchymal and endothelial lineage differentiation. Fmcs expressing hematopoietic markers were hypothesized to have a role in the attack to neoplastic cells, whereas those expressing epithelial or mesenchymal antigens could be involved in repair and replacement of damaged cells. On the other hand, fetal cells showing an endothelial phenotype could have a role in tumor evolution and progression. The positive effect of FCM is supported by findings in animal models. Conclusions: This review provides an extensive overview of the link between fetal cell microchimerism and maternal cancers. Moreover, biological mechanisms by which fetal cell microchimerism is believed to modulate the protection against cancer development or tumor progression will be discussed, together with findings in animal models.

AB - Introduction: Fetal cell microchimerism (FCM) is defined as the persistence of fetal cells in the mother for decades after pregnancy without any apparent rejection. Fetal microchimeric cells (fmcs) engraft the maternal bone marrow and are able to migrate through the circulation and to reach tissues. In malignancies, the possible role of fmcs is still controversial, several studies advising a protective and repairing function, and other postulating a beneficial role in the progression of the disease. At the peripheral blood level, FCM is less frequently observed in women with several solid and hematological neoplasia with respect to healthy controls, suggesting a beneficial role in cancer surveillance. At the tissue level, fmcs were documented in neoplastic lesions of thyroid, breast, cervix, lung and melanoma, displaying epithelial, hematopoietic, mesenchymal and endothelial lineage differentiation. Fmcs expressing hematopoietic markers were hypothesized to have a role in the attack to neoplastic cells, whereas those expressing epithelial or mesenchymal antigens could be involved in repair and replacement of damaged cells. On the other hand, fetal cells showing an endothelial phenotype could have a role in tumor evolution and progression. The positive effect of FCM is supported by findings in animal models. Conclusions: This review provides an extensive overview of the link between fetal cell microchimerism and maternal cancers. Moreover, biological mechanisms by which fetal cell microchimerism is believed to modulate the protection against cancer development or tumor progression will be discussed, together with findings in animal models.

KW - Cancer

KW - Fetal cells

KW - Microchimerism

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84953372293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953372293&partnerID=8YFLogxK

U2 - 10.1007/s00432-015-2110-3

DO - 10.1007/s00432-015-2110-3

M3 - Article

AN - SCOPUS:84953372293

VL - 142

SP - 1697

EP - 1704

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 8

ER -